Logo image
The effect of renal function on enalapril kinetics
Journal article   Peer reviewed

The effect of renal function on enalapril kinetics

D T Lowenthal, J D Irvin, D Merrill, S Saris, E Ulm, S Goldstein, M Hichens, L Klein, A Till and K Harris
Clinical pharmacology and therapeutics, v 38(6), pp 661-666
Dec 1985
PMID: 2998676

Abstract

Enalapril maleate (MK‐421), a nonmercapto‐containing angiotensin converting enzyme (ACE) inhibitor, is converted in vivo to enalaprilat (MK‐422), the active diacid. We evaluated serum profiles and urinary excretion of oral enalapril maleate in patients with renal disease (group I, creatinine clearance <3 ml/ min, patients undergoing dialysis, n = 10; group II, creatinine clearance 10 to 79 ml/min, n = 9) compared with healthy subjects (group III, creatinine clearance >80 ml/min, n = 10). Group I received a 10 mg dose during a day while not receiving dialysis and a 10 mg dose 1 hour before dialysis 2 weeks later. Groups II and III received a single 10 mg dose. Blood samples and urine were collected for 48 hours. Impaired renal function resulted in elevated serum and plasma concentrations of enalapril maleate and decreased excretion rates and urinary recovery of enalapril maleate and enalaprilat. The data suggest an apparent increase in the extent of metabolism of enalapril maleate to enalaprilat or an increase in nonrenal elimination of unchanged enalapril maleate in renal disease compared with normal health. Enalaprilat was dialyzable. Clinical Pharmacology and Therapeutics (1985) 38, 661–666; doi:10.1038/clpt.1985.242

Metrics

14 Record Views
41 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Pharmacology & Pharmacy
Logo image